Combined use of docetaxel and bone marrow mesenchymal stem cells in human hepatoma cell line SMMC-7721

doi:10.3969/j.issn.2095-4344.2016.24.009

Abstract

Abstract:

BACKGROUND: Docetaxel, a cell cycle specific anti-tumor drug, is a drug that is used primarily for treating breast cancer; however, its efficacy is low when used for treatment of cancer not sensitive to radiotherapy. Bone marrow mesenchymal stem cells have been shown to strengthen the effects of tumor-specific targeting chemotherapy drugs.
OBJECTIVE: To investigate the effects of docetaxel combined with bone marrow mesenchymal stem cells (BMSCs) on human hepatoma cell line SMMC-7721.
METHODS: BMSC cells were cultured in vitro. The logarithmic growth of SMMC-7721 hepatoma cells were randomly divided into blank control group, BMSCs group and combined treatment group (combined treatment of BMSCs and docetaxel). SMMC-7721 cell cycle was detected using flow cytometry. Cell growth rate of SMMC-7721 was determined by MTT assay. mRNA and protein expressions of tumor suppressor genes PTEN and p53 were detected by reverse transcription polymerase chain reaction and western blot assay.
RESULTS AND CONCLUSION: Combined treatment of docetaxel and BMSCs inhibited SMMC-7721 cell proliferation. Compared with the blank control group, the number of cells at the G0/G1 phase was significantly increased in BMSCs group and combined treatment group. The cell growth rate of SMMC-7721 was significantly inhibited in BMSCs group compared with the blank control group, and that was further inhibited in combined treatment group (P < 0.05). mRNA and protein expression of PTEN and p53 were significantly increased in combined treatment group compared with BMSCs group and blank control group (P < 0.05). Our results suggest that BMSCs inhibit the growth of SMMC-7721 cells, and combined use of docetaxel and BMSCs strengthens the antitumor effect of BMSCs.

中国组织工程研究杂志出版内容重点：组织构建；骨细胞；软骨细胞；细胞培养；成纤维细胞；血管内皮细胞；骨质疏松；组织工程

Key words: Liver Neoplasms, Mesenchymal Stem Cells, Stem Cells

CLC Number:

R318

Li Jing-yun, Jiao Ting. Combined use of docetaxel and bone marrow mesenchymal stem cells in human hepatoma cell line SMMC-7721[J]. Chinese Journal of Tissue Engineering Research, 2016, 20(24): 3555-3561.

Figures/Tables 3

References

[1] 马友龙,祁海艳,曹振东,等.多西紫杉醇纳米脂质体的制备及其对肝癌细胞的体内外治疗研究[J].中国生化药物杂志, 2015,37(6):43-47.
[2] 何迷,王家平,张磊,等.多西紫杉醇在肝癌细胞裸鼠肝脏移植瘤中对P53、VEGF作用的研究[J].昆明医科大学学报, 2015,36(1):43-47.
[3] Schmid SC, Geith A, Böker A,et al.Enzalutamide after docetaxel and abiraterone therapy in metastatic castration-resistant prostate cancer.Advances in therapy. 2014;31(2):234-241.
[4] 熊志勇,姚志成,颜见,等.肝癌细胞促进骨髓间充质干细胞向肿瘤相关成纤维细胞转化[J].中华实验外科杂志, 2015, 32(8):1884-1887.
[5] 魏兰镔,赵凌云,庞瑞,等.多西紫杉醇用于肿瘤热化疗的体外研究[J].现代肿瘤医学,2014,22(04):746-751.
[6] Figg WD,Woo S,Zhu W,et al.A phase I clinical study of high dose ketoconazole plus weekly docetaxel for metastatic castration resistant prostate cancer.J Urol. 2010 Jun;183(6):2219-2226.
[7] 邬杰忠,邓美海,钟跃思,等.骨髓和肝癌来源间充质干细胞对肝癌细胞HepG2增殖、侵袭能力的影响[J].中华实验外科杂志,2015,32(3):499-501.
[8] 郑宏志,张悦,周晓东,等.载多西紫杉醇脂质微泡对人肝癌HepG2细胞抑制作用的体外研究[J].现代生物医学进展, 2013,13(30):5806-5810.
[9] 张彤,段仁慧,张蕊.吉西他滨联合多西紫杉醇方案治疗晚期肝癌的临床观察[J].肿瘤防治研究 2012,39(11):1369-1372.
[10] Egawa T, Okubo Y, Kemmochi T, et al.A case of liver metastasis from esophageal cancer treated with stereotactic body radiation therapy. Gan To Kagaku Ryoho.2013;40(12):1850-1852.
[11] Shibata S, Toyoki Y, Akasaka H,et al.A case of metastaticlivertumor arising from gastriccancerresected after second-line chemotherapy. Gan To Kagaku Ryoho. 2014;41(12):2355- 2357.
[12] 胡方方,周家华,郑国灿,等.骨髓间充质干细胞对肝癌大鼠血管生成和细胞增殖的影响[J].中国老年学杂志,2015, 36(12):3226-3228.
[13] 刘有恒,费洪新,吕艳欣,等.多西紫杉醇对缺氧人肝癌细胞株SMMC7721化疗药物的敏感性及其作用机制[J].中国医药导报,2012,9(12):26-28.
[14] Eckmann K, Michaud LB, Rivera E,et al.Pilot study to assess toxicity and pharmacokinetics of docetaxel in patients with metastatic breast cancer and impaired liver function secondary to hepatic metastases. J Oncol Pharm Pract.2014;20(2):120-129.
[15] 张文君,刘芹.多西紫杉醇载药纳米粒子对小鼠肝癌移植瘤的靶向治疗作用[J].实用临床医药杂志,2012,16(5):1-3,6.
[16] 陈琪枫,方晓明,姚宁,等.人骨髓间充质干细胞对肝癌细胞的生物学效应[J].中国组织工程研究,2015,19(10): 1511-1515.
[17] 李天然,赵绍宏,周军,等. 人骨髓间充质干细胞TGFβ-1基因沉默对肝癌细胞的影响[J].实用临床医药杂志, 2015, 19(3):10-14.
[18] Ren KQ, Cao XZ, Liu ZH, et al.8-bromo-5-hydroxy-7- methoxychrysin targeting for inhibition of the properties of liver cancer stem cells by modulation of Twist signaling.Int J Oncol.2013;43(5):1719-1729.
[19] 康娟,吴小翎,张勇,等.载多西紫杉醇脂质超声微泡造影剂对兔VX2肝癌增殖和凋亡的作用[J].中国超声医学杂志, 2009,25(7):642-645.
[20] 王海霞.多西紫杉醇诱导SMMC-7721肝癌细胞凋亡中的氧化-抗氧化失衡研究[J].肿瘤学杂志,2008,14(6): 432-434.
[21] Li X, Song Z, Zhong H, et al.Effect of depsides salts from Salvia miltiorrhiza on human hepatoma cell line SMMC-7721 subcutaneous xenografts in nude mice. Medical sciences.2015;40(2):158-164.
[22] 张静,张贤彬,巩鹏.骨髓间充质干细胞对肝癌影响作用的研究进展[J].国际外科学杂志,2015,42(1):64-66.
[23] 叶健文,周闯,阎冰,等.钙网蛋白基因沉默对人肝癌细胞的增殖及侵袭能力的影响[J].中华肝胆外科杂志, 2015, 21(6): 405-409.
[24] 董明,侯俊明,高美花,等.黄芩苷对肝癌细胞株SMMC- 7721裸鼠移植瘤生长抑制作用及其机制[J].现代肿瘤医学,2014,22(2):256-258.
[25] Hu BS, Tan JW, Zhu GH, et al.WWOX induces apoptosis and inhibits proliferation of human hepatoma cell line SMMC-7721. World J Gastroenterol. 2012; 18(23):3020-3026.
[26] 张浩,刘小方,李昱骥,等. 多西紫杉醇诱导人肝癌细胞凋亡及其机制的研究[J].中华肝胆外科杂志,2008,14(12): 901-903.
[27] 王强,巩鹏,金实,等. 磁标记骨髓间充质干细胞对不同转移潜能肝癌细胞作用的研究[J].大连医科大学学报, 2015, 37(1):13-16.
[28] Bao YR, Wang S, Meng XS,et al.Effect of flavonoids of polygoni orientails fructus on human hepatoma cell line SMMC-7721. Zhong Yao Cai. 2013;36(2):255-259.
[29] 王雪峰,梅佳玮,廖传文,等.骨髓间充质干细胞与小鼠肝癌肝移植术后复发关系的实验观察[J].中华医学杂志, 2014, 94(6):455-458.
[30] 何迷,王家平,张磊,等.多西紫杉醇在肝癌细胞裸鼠肝脏移植瘤中对P53、VEGF作用的研究[J]. 昆明医科大学学报, 2015,36(1):43-47.
[31] 袁博,陈昆仑,张岚,等. 大鼠骨髓间充质干细胞对RH-35肝癌细胞侵袭能力的影响[J].西安交通大学学报(医学版), 2014,35(4):455-459.
[32] 李天然,卢光明,宋斌,等.骨髓间充质干细胞对高低转移潜能肝癌细胞影响的实验研究[J].胃肠病学和肝病学杂志, 2014,23(9):1056-1060.
[33] Yang X,Wang D,Dong W,et al.Suppression of Na+/H +exchanger 1 by RNA interference or amiloride inhibits human hepatoma cell line SMMC-7721 cell invasion. Med Oncol. 2011;28(1):385-390.